



ASX ANNOUNCEMENT

January 27th, 2006

GTG Expands Licensing Programme in USA

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce it has appointed the firm of PatentBridge LLC, based in Silicon Valley, California, to help rapidly expand its licensing programme in the USA.

This appointment follows the settlement of all past lawsuits which challenged the GTG non-coding patents. As previously reported, GTG has now prevailed in six out of six law suits involving its non-coding patents, and today, there is no party anywhere in the world legally challenging these patents.

Accordingly, GTG is now actively expanding its global licensing programme through the recruitment of additional licensing resources and legal support teams – in Australia, in North America, in Europe and in Asia. The appointment of PatentBridge is the first step in this programme. GTG intends to make further appointments to expand its licensing program - in USA, Europe and the Asia Pacific region.

About the GTG non-coding patents. The GTG non-coding patents have now issued in all 24 countries in which they were originally filed. GTG seeks to make its patents widely available and has so far issued 29 licenses. Of these, 24 are to commercial entities for a total value of approximately A\$53 million. As previously reported, GTG has identified numerous other parties who may benefit from taking a license to the non-coding patents. These parties are now being followed up.

About PatentBridge. PatentBridge is a privately held patent licensing company, specialising in the representation of select patents covering extraordinary scientific and industrial breakthroughs. The founder and CEO of PatentBridge, Mark S. Holmes, is recognised as one of the pre-eminent patent licensing experts in the United States. Mr. Holmes earned his Engineering degree from Brown University and has worked as a registered patent attorney since 1985. Mr. Holmes lectures widely on patent licensing and is the author of the widely-read treatise “Patent Licensing: Strategy, Negotiation and Forms”. Mr. Holmes has also established a track record for helping licensors achieve significant success over the last 20 years.

FOR FURTHER INFORMATION PLEASE CONTACT

Dr. Mervyn Jacobson
Chief Executive Officer

Genetic Technologies Limited (ABN 17 009 212 328)
Phone: +61 3 9415 1135